Identity
DNA/RNA

Expression
Wide: brain, placenta, testis, tonsils (mRNA); in mice: protein expression predominant in lymphoid organs, testis, ovary.
Localisation
Both cytoplasmic and nuclear.
Function
Part of the FA complex with FANCC, FANCE, FANCF, and FANCG; this complex is only found in the nucleus. FANCA and FANCG form a complex in the cytoplasm, through a N-term FANCA (involving the nuclear localization signal) -FANCG interaction; FANCC join the complex; phosphorylation of FANCA would induce its translocation into the nucleus.This FA complex translocates into the nucleus, where FANCE and FANCF are present; FANCE and FANCF join the complex. The FA complex subsequently interacts with FANCD2 by monoubiquitination of FANCD2 during S phase or following DNA damage. Activated (ubiquinated) FANCD2, downstream in the FA pathway, will then interact with other proteins involved in DNA repair, possibly BRCA1; after DNA repair, FANCD2 return to the non-ubiquinated form.
Homology
No known homology or functional motifs.
Mutations
Germinal
Various nucleotide substitutions, deletions, or insertions have been described. Over 90% of the mutations are private, with about 30% being relatively large deletions. Founder mutations have been described in South Africa.
Implicated in
Fanconi anaemia (FA)
FANCA is implicated in the FA complementation group A; it represents about 70% of FA cases. Disease Fanconi anaemia is a chromosome instability syndrome/cancer prone disease (at risk of leukaemia and squamous cell carcinoma). Prognosis Fanconi anaemia's prognosis is poor; mean survival is 20 years: patients die of bone marrow failure (infections, haemorrhages), leukaemia, or solid cancer. It has recently been shown that significant phenotypic differences were found between the various complementation groups. In FA group A, patients homozygous for null mutations had an earlier onset of anemia and a higher incidence of leukemia than those with mutations producing an altered protein. Patients homozygous for null mutations in FANCA are highrisk groups with a poor hematologic outcome and should be considered as candidates both for frequent monitoring and early therapeutic intervention. Cytogenetics Spontaneously enhanced chromatid-type aberrations (breaks, gaps, interchanges; increased rate of breaks compared to control, when induced by specific clastogens known as DNA cross-linking agents (e.g. mitomycin C, diepoxybutane).
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